Testing WangBi granules for rheumatoid arthritis along with standard care
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial studies whether WangBi granules help control rheumatoid arthritis symptoms when used by people already taking stable methotrexate and tofacitinib. It’s mainly for people with mild-to-moderate disease activity and specific diagnostic features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 75 years old.
- Have rheumatoid arthritis that meets standard classification rules (ACR 1987 or ACR/EULAR 2010).
- Also meet a specific Chinese-medicine pattern described as “kidney deficiency, dampness, and blockage of channels.”
- Have rheumatoid arthritis activity score DAS28 between 2.6 and 3.2.
- Be taking methotrexate (7.5–15 mg once weekly) and tofacitinib (5 mg twice daily) regularly for at least 4 weeks, without changing doses.
- Have no major health problems that can affect safety (such as serious liver/kidney issues, cancer, or severe blood problems) and agree to participate in writing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether transferring healthy gut bacteria from a donor to patients with rheumatoid arthritis that hasn't improved on standard medications can reduce joint pain and swelling. The goal is to see if rebalancing the gut microbiome (the community of bacteria in your intestines) helps control inflammation.
This trial tests a new treatment called SWK002 for people with rheumatoid arthritis that hasn't improved after trying multiple medications. It aims to see if SWK002 can help when other treatments have failed.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This trial tests whether adding Huoluo Pills, a traditional Chinese medicine, to the standard drug iguratimod helps reduce joint pain and swelling better than iguratimod alone. If you have mild to moderate rheumatoid arthritis, this study might offer a new option.
This trial tests a new experimental antibody called GNC-038 for people with moderate to severe rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if targeting specific immune cells can reduce inflammation and improve symptoms.
This Phase 3 study compares two ways to treat active rheumatoid arthritis: a TNF-blocking biologic versus a targeted pill treatment. It may help people who are not doing well on (or cannot tolerate) certain biologic therapies to find a better, more practical option.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.